VANCOUVER, BC, Aug. 15, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”), a special purpose acquisition company (“SPAC”), today announced the filing of a registration statement by 1427702 B.C. Ltd. (“TopCo”) on Form F-4…

Source

Previous articleatai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
Next articlePT432 – From NBA Dreams to Cultural Healing: Iboga and a Mission to Empower Gabon